JM Financial calls Metropolis Healthcare the best-value diagnostic stock, sees 27.2% upside
Key Takeaways
- •JM Financial kept a Buy rating on Metropolis Healthcare with a target price of Rs 734.
- •The target price implies an upside of 27.2% from the current level.
- •The brokerage said Metropolis Healthcare is the cheapest among India’s leading listed diagnostic companies.
- •Valuation, network expansion, B2C growth and margin improvement were cited as the main reasons for the positive view.
- •The note was framed as a valuation-led call within a diagnostics sector that remains closely watched by investors.
JM Financial has retained its Buy rating on Metropolis Healthcare and set a target price of Rs 734, implying an upside of 27.2%.
The brokerage described Metropolis Healthcare as the cheapest among India’s leading listed diagnostic players, citing attractive valuations, network expansion, stronger B2C growth and improving margins as the main drivers behind its stance.
The note comes as the diagnostic industry continues to draw investor attention, with listed players being tracked closely for growth in diagnostic services, consumer-facing business and operating profitability. In that context, the brokerage’s call highlights how valuation, scale and margin trends remain central to how the market assesses diagnostics companies.
Among the stocks listed in the same segment, the article also references JM Financial, Choice International, IIFL Capital Services, Anand Rathi Share & Stock Brokers and 5Paisa Capital.
Live market tracking and related coverage were also featured alongside the report, including updates on Sensex and Nifty, stock tips, Budget 2025 coverage and other market commentary on ETMarkets.
The article also linked to related Economic Times coverage on IndiGo and Air India pilot shortages, CFO resignations, the FCNR (B) scheme, Power Grid Corp, US bond yields and BEL.
JM Financial’s view on Metropolis Healthcare was presented as a valuation-led stock call, with the brokerage highlighting the company’s position within India’s listed diagnostic space and its expectations for continued operational improvement.
